» Articles » PMID: 17385015

Enhanced Intercellular Retention Activity of Novel PH-sensitive Polymeric Micelles in Wild and Multidrug Resistant MCF-7 Cells

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2007 Mar 27
PMID 17385015
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this work was to demonstrate the advantage of using pH-sensitive polymeric mixed micelles (PHSM) composed of poly(L: -histidine) (polyHis)/poly(ethylene glycol) (PEG) and poly(L: -lactic acid) (pLLA)/PEG block copolymers with folate conjugation to increase drug retention in wild-type and MDR tumor cells.

Materials And Methods: Both wild-type and multidrug resistant (MDR) human breast adenocarcinoma (MCF-7) cell lines were used to investigate the accumulation and elimination of doxorubicin (DOX), PHSM with folate (PHSM/f), and pH-insensitive micelles composed of pLLA/PEG block copolymer with folate (PHIM/f).

Results: Cells treated with PHSM/f showed decelerated elimination kinetics compared to cells treated with PHIM/f. MDR cells treated with drug-containing PHSM/f for 30 min retained 80% of doxorubicin (DOX) even after incubation for 24 h in the absence of drug. On the other hand, cells treated with drug-containing PHIM/f retained only 40% of DOX within the same period of time. Flow cytometry and confocal microscopy confirmed these results.

Conclusions: Cellular entry of the micelles occurred via receptor-mediated endocytosis using folate receptors. The pH-induced destabilization of PHSM/f led to rapid distribution of drug and polymer throughout the cells, most likely due to polyHis-mediated endosomal disruption. This reduced the likelihood of drug efflux via exocytosis from resistant tumor cells.

Citing Articles

An Updated Insight into Phytomolecules and Novel Approaches used in the Management of Breast Cancer.

Nooreen Z, Tandon S, Wal A, Rai A Curr Drug Targets. 2024; 25(3):201-219.

PMID: 38231060 DOI: 10.2174/0113894501277556231221072938.


Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers.

Ashique S, Garg A, Hussain A, Farid A, Kumar P, Taghizadeh-Hesary F Cancer Med. 2023; 12(18):18797-18825.

PMID: 37668041 PMC: 10557914. DOI: 10.1002/cam4.6502.


Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer.

Kafle U, Agrawal S, Dash A Pharmaceutics. 2022; 14(12).

PMID: 36559276 PMC: 9785637. DOI: 10.3390/pharmaceutics14122783.


Nanotechnological approaches for counteracting multidrug resistance in cancer.

Martinelli C, Biglietti M Cancer Drug Resist. 2022; 3(4):1003-1020.

PMID: 35582219 PMC: 8992571. DOI: 10.20517/cdr.2020.47.


Drug delivery approaches for breast cancer.

Singh S, Singh S, Lillard Jr J, Singh R Int J Nanomedicine. 2017; 12:6205-6218.

PMID: 28883730 PMC: 5576701. DOI: 10.2147/IJN.S140325.


References
1.
Naito S, Yokomizo A, Koga H . Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol. 1999; 6(9):427-39. DOI: 10.1046/j.1442-2042.1999.00088.x. View

2.
Cataldo A, Petanceska S, Peterhoff C, Terio N, Epstein C, Villar A . App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci. 2003; 23(17):6788-92. PMC: 6740714. View

3.
Assaraf Y, Rothem L, Hooijberg J, Stark M, Ifergan I, Kathmann I . Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem. 2002; 278(9):6680-6. DOI: 10.1074/jbc.M209186200. View

4.
Wang C, Huang L . Polyhistidine mediates an acid-dependent fusion of negatively charged liposomes. Biochemistry. 1984; 23(19):4409-16. DOI: 10.1021/bi00314a026. View

5.
Hooijberg J, Peters G, Assaraf Y, Kathmann I, Priest D, Bunni M . The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem Pharmacol. 2003; 65(5):765-71. DOI: 10.1016/s0006-2952(02)01615-5. View